Saturday, 22 August 2026
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Headline and excerpt published by New York Times. The full article is on their site.
Analysing which companies this story affects.
Done here?
Read the full story at New York TimesModerna's pivot from pandemic-dependent Covid vaccine revenues to oncology therapeutics reduces single-product concentration risk and reopens growth avenues in a large therapeutic market.
Generated by a language model from the headline and excerpt above. It describes possible exposure and direction only — not a forecast, valuation, or recommendation. Verify before acting on anything here.